Archemin

Advice & reporting for the chemical and pharmaceutical industries

Adreview reimbursed in Belgium (Class I reimbursement)

Fri, 01/06/2012 - 4:39pm -- Inneke Van de Vijver

As from 1 June 2012 on Adreview is reimbursed in Belgium when used in clinical cardiology for identifying patients most in need of additional medical treatment or the implantation of a cardiac defibrillator.

The GE Healthcare product Adreview ([123I]mIBG) is is an analogue of the neurotransmitter norepinephrine, and uptake of this compound reflects the extent of sympathetic innervation in tissues such as the myocardium. Numerous studies have demonstrated that low myocardial [123I]mIBG uptake is commonly found in symptomatic heart failure patients (functional NYHA class 2 or 3) and is an independent predictor of adverse long-term outcome.

The ADMIRE-HF study confirmed the increased occurrence of adverse outcomes in patients with symptomatic heart failure based upon the heart/mediastinum (H/M) ratio on late (“delayed”) planar [123I]mIBG images.